Compare Diamondback Energy Inc (FANG) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Cassava Sciences Inc — how do they compare? Diamondback Energy Inc trades at $192.13 (market cap $53.67B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Diamondback Energy Inc is far larger — about 1362.2× Cassava Sciences Inc's market cap, and Diamondback Energy Inc pays a 2.3% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Cassava Sciences Inc for 37 Days on average.
| FANG | FLNA | |
|---|---|---|
Market Cap | $53.67B | $39.40M |
Volume | 2,250,644 | 759,018 |
Sector | Energy | Health |
52-Week High | $213.69 | $4.64 |
52-Week Low | $137.29 | $0.68 |
Typical Hold Time | 69 Days | 37 Days |
Enterprise Value | $65.83B | -$43.28M |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.68, up 3.96% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with revenue growth from $14.93B in 2025 to projected $17.0B in 2026, though net margins have compressed. Recent earnings beat expectations in Q1 and Q2 2026, while technical indicators show the stock trading near pivot point resistance at $191 with overall bullish moving average signals.
FANG presents a compelling investment case with 91% analyst buy ratings and a $231.77 price target offering 21% upside. Key opportunities include strong Permian Basin positioning and dividend growth, while risks include oil price volatility and insider selling activity. The company's solid cash flow generation supports continued shareholder returns despite margin pressure from rising costs.
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
